Subsequent primary malignancies and acute myelogenous leukemia transformation among myelodysplastic syndrome patients treated with or without lenalidomide

Subsequent primary malignancies and acute myelogenous leukemia transformation among myelodysplastic syndrome patients treated with or without lenalidomide

The few studies that have examined rates of acute myeloid leukemia (AML) transformation in lenalidomide‐treated myelodysplastic syndrome (MDS) patients have been limited to deletion 5q MDS. The association between lenalidomide and subsequent primary malignancies (SPMs) in MDS patients has not been e...

Full description

Bibliographic Details
Main Authors: Rollison, Dana E., Shain, Kenneth H., Lee, Ji‐Hyun, Hampras, Shalaka S., Fulp, William, Fisher, Kate, Al Ali, Najla H., Padron, Eric, Lancet, Jeffrey, Xu, Qiang, Olesnyckyj, Martha, Kenvin, Laurie, Knight, Robert, Dalton, William, List, Alan, Komrokji, Rami S.
Format: Online
Language:English
Published: John Wiley and Sons Inc. 2016
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4944897/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4944897/

Similar Items